Research programme: diabetes therapy - BioVisioN/Novo Nordisk
Alternative Names: Diabetes therapy research programme - BioVisioN/Novo NordiskLatest Information Update: 23 Feb 2011
At a glance
- Originator Digilab BioVisioN; Novo Nordisk
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 09 Mar 2006 BioVisioN is now called Digilab BioVision GmbH
- 30 May 2002 Preclinical trials in Type-2 diabetes mellitus in Denmark (unspecified route)
- 30 May 2002 Preclinical trials in Type-2 diabetes mellitus in Germany (unspecified route)